Victor Harrell
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Viiv Healthcare Company at 30.4% of the total. Reporting peaked in 2022 at $3,070 and has fallen 60.5% since, to $1,214 in 2025. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 479 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Gilead$3K
- Johnson & Johnson$642
- Merck$538
- Otsuka America Pharmaceutical, Inc.$409
- Novo Nordisk$397
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$510%
- Food & beverage$10,88699%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 170 | $3,355 |
| Gilead | 135 | $3,034 |
| Johnson & Johnson(2 entities) | 30 | $642 |
| Merck | 25 | $538 |
| Otsuka America Pharmaceutical, Inc. | 4 | $409 |
| Novo Nordisk | 19 | $397 |
| Janssen Products, LP | 3 | $346 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $265 |
| Theratechnologies Inc. | 8 | $204 |
| AbbVie | 10 | $199 |
| Lundbeck LLC | 9 | $191 |
| Axsome Therapeutics, Inc. | 4 | $188 |
| Teva Pharmaceuticals USA, Inc. | 3 | $166 |
| Napo Pharmaceuticals Inc | 6 | $122 |
| Global Blood Therapeutics, Inc. | 1 | $122 |
| Lilly USA, LLC | 6 | $99 |
| Shionogi Inc | 4 | $98 |
| Bayer | 1 | $97 |
| Exact Sciences | 3 | $73 |
| Biohaven Pharmaceuticals, Inc. | 4 | $70 |
| Genentech USA, Inc. | 5 | $63 |
| EMD Serono, Inc. | 1 | $48 |
| Boehringer Ingelheim | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Janssen Scientific Affairs, LLC | 2 | $25 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Boston Scientific | 1 | $21 |
| Clarus Therapeutics Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| AstraZeneca | 1 | $16 |
| Seqirus USA Inc | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,036 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 240 | $936,628 |
| DovatoDolutegravir Sodium/Lamivudine | 53 | $146,117 |
| CabenuvaCabotegravir/Rilpivirine | 19 | $126,157 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 25 | $109,747 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 30 | $101,113 |
| JulucaDolutegravir/Rilpivirine | 29 | $98,773 |
| DescovyEmtricitabine/Tenofov Alafenam | 31 | $66,400 |
| TivicayDolutegravir Sodium | 24 | $50,736 |
| MounjaroTirzepatide | 38 | $38,613 |
| TrulicityDulaglutide | 34 | $31,470 |
| TrintellixVortioxetine Hydrobromide | 22 | $10,731 |
| JardianceEmpagliflozin | 11 | $6,402 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 19 | $1,716 |
| Ventolin HfaAlbuterol Sulfate | 24 | $1,339 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 53 | $1,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $3,034 | $1,003,028271 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Juluca, Tivicay | $3,355 | $421,783125 claims |
| Janssen Products, LPSymtuza | $346 | $109,74725 claims |
| Lilly USA, LLCMounjaro, Trulicity | $99 | $70,08272 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $44 | $10,73122 claims |
| Boehringer IngelheimJardiance | $45 | $6,40211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Flint
- Margaret CoeFlint$12K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.